Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 32 articles: HTML format

Single Articles

October 2026
1. PORCEL JM
   Don't discard the supernatant: pleural fluid cfDNA for molecular profiling in lung cancer.
   Eur Respir J. 2026 Oct 29:2601861. doi: 10.1183/13993003.01861-2026.
   PubMed     Abstract available
   
   
   
2. O'DOWD EL, Baldwin DR
   Reply: ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.
   Eur Respir J. 2026;68:2601568.
   PubMed    
   
   
   
3. ROSSI SH, Byass O, Bakewell R, Barrett T, et al
   Comment on: ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.
   Eur Respir J. 2026;68:2601081.
   PubMed    
   
   
   September 2026
4. NOORDHOF AL, Damhuis RAM, Blyth KG, van Schil PE, et al
   Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy.
   Eur Respir J. 2026 Sep 7:2600555. doi: 10.1183/13993003.00555-2026.
   PubMed     Abstract available
   
   
   June 2026
5. BAKER JR, Beaulieu D, Avci E, Huang E, et al
   Hallmarks of the ageing lung: 10 years later.
   Eur Respir J. 2026;67:2501272.
   PubMed     Abstract available
   
   
   May 2026
6. KOREVAAR DA, Kovacevic B, Papadopoulou E, van den Broek FJC, et al
   ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
   Eur Respir J. 2026 May 21:2600097. doi: 10.1183/13993003.00097-2026.
   PubMed     Abstract available
   
   
   
7. CLEMENTS D, Babaei-Jadidi R, Johnson J, Miller S, et al
   Extracellular matrix deposition drives disease progression and reduces rapamycin response in lymphangioleiomyomatosis.
   Eur Respir J. 2026;67:2500492.
   PubMed     Abstract available
   
   
   April 2026
8. BRUNELLI A, Hardavella G, Huber RM, Berghmans T, et al
   Reply regarding the European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer.
   Eur Respir J. 2026;67:2502601.
   PubMed    
   
   
   
9. HEDMAN K, Kristenson K
   Comment on: European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer.
   Eur Respir J. 2026;67:2502480.
   PubMed     Abstract available
   
   
   March 2026
10. KIM H, Jo E, Kim J, Ho Yoon S, et al
    Associations between High-Density Lipoprotein Cholesterol and Interstitial Lung Abnormalities in the Korean National Lung Cancer Screening.
    Eur Respir J. 2026 Mar 19:2501878. doi: 10.1183/13993003.01878-2025.
    PubMed     Abstract available
    
    
    
11. KUO YW, Chen YL, Chen YH, Chang YL, et al
    Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial.
    Eur Respir J. 2026;67:2402370.
    PubMed     Abstract available
    
    
    November 2025
12. LIU HJ, Diesler R, Chami J, Wu B, et al
    Modulation of infiltrating CD206(+) macrophages restricts progression of pulmonary lymphangioleiomyomatosis.
    Eur Respir J. 2025;66:2500084.
    PubMed     Abstract available
    
    
    
13. BRUNELLI A, Hardavella G, Huber RM, Berghmans T, et al
    European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer.
    Eur Respir J. 2025;66:2500156.
    PubMed     Abstract available
    
    
    September 2025
14. IMAI R, Fukui S, Inoue K
    Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks.
    Eur Respir J. 2025;66:2500453.
    PubMed    
    
    
    
15. YOON HY, Song JW
    Reply to: Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks.
    Eur Respir J. 2025;66:2501350.
    PubMed    
    
    
    June 2025
16. SHEIKH M, Weiderpass E
    Lung cancer screening in Europe: a golden opportunity to address tobacco use through scalable, WHO-guided cessation interventions.
    Eur Respir J. 2025;65:2500124.
    PubMed    
    
    
    May 2025
17. SELMAN M, Buendia-Roldan I, Pardo A
    Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.
    Eur Respir J. 2025;65:2402418.
    PubMed     Abstract available
    
    
    March 2025
18. RATSIHORIMANANA R, Maitre T, Dusselier M, Triet Ngo M, et al
    Recurrent respiratory papillomatosis in adults with lower respiratory tract involvement: a retrospective study of the OrphaLung and GETIF networks.
    Eur Respir J. 2025;65:2400618.
    PubMed     Abstract available
    
    
    December 2024
19. WENG C, Zhao Y, Song M, Shao Z, et al
    Mosaic loss of chromosome Y, tobacco smoking and risk of age-related lung diseases: insights from two prospective cohorts.
    Eur Respir J. 2024;64:2400968.
    PubMed     Abstract available
    
    
    November 2024
20. YOON HY, Kim H, Bae Y, Song JW, et al
    Pirfenidone and risk of lung cancer development in IPF: a nationwide population-based study.
    Eur Respir J. 2024 Nov 7:2401484. doi: 10.1183/13993003.01484-2024.
    PubMed     Abstract available
    
    
    June 2024
21. D'AMOURS MF, Wu FTH, Theisen-Lauk O, Chan EK, et al
    Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach.
    Eur Respir J. 2024 Jun 6:2400332. doi: 10.1183/13993003.00332-2024.
    PubMed     Abstract available
    
    
    
22. SEIJO LM, Zulueta JJ
    The tip of the iceberg: a plethora of lung nodules in the general population.
    Eur Respir J. 2024;63:2400889.
    PubMed    
    
    
    
23. CAI J, Vonder M, Du Y, Pelgrim GJ, et al
    Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach.
    Eur Respir J. 2024;63:2301736.
    PubMed     Abstract available
    
    
    
24. PORCEL JM
    Pleural mesothelioma: surgery questioned again?
    Eur Respir J. 2024;63:2400896.
    PubMed    
    
    
    
25. RASKIN J, Surmont V, Maat APWM, Yahia M, et al
    A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205.
    Eur Respir J. 2024;63:2302114.
    PubMed     Abstract available
    
    
    May 2024
26. SESE L, Annesi-Maesano I
    Lung cancer and idiopathic pulmonary fibrosis: environmental exposures are the key.
    Eur Respir J. 2024;63:2400760.
    PubMed    
    
    
    April 2024
27. BRUDON A, Legendre M, Mageau A, Bermudez J, et al
    High risk of lung cancer in surfactant-related gene variant carriers.
    Eur Respir J. 2024 Apr 4:2301809. doi: 10.1183/13993003.01809-2023.
    PubMed     Abstract available
    
    
    
28. LEWIS KE
    Smoking cessation at lung cancer screening: joining (life-saving) dots.
    Eur Respir J. 2024;63:2400550.
    PubMed    
    
    
    March 2024
29. YOON HY, Kim SY, Song JW
    Association Between High Levels of Nitrogen Dioxide and Increased Cumulative Incidence of Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis.
    Eur Respir J. 2024 Mar 7:2301181. doi: 10.1183/13993003.01181-2023.
    PubMed     Abstract available
    
    
    February 2024
30. 
    "ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer." E.L. O'Dowd, I. Tietzova, E. Bartlett, et al. Eur Respir J 2023; 62: 2300533.
    Eur Respir J. 2024;63:2350533.
    PubMed    
    
    
    January 2024
31. OBACZ J, Valer JA, Nibhani R, Adams TS, et al
    Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma.
    Eur Respir J. 2024;63:2300143.
    PubMed     Abstract available
    
    
    October 2023
32. O'DOWD EL, Tietzova I, Bartlett E, Devaraj A, et al
    ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.
    Eur Respir J. 2023 Oct 6:2300533. doi: 10.1183/13993003.00533-2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum